Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
IL5 mAb | Monospecific antibody | Immunological disease | Asthma | Phase II | Global (except China) |
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
IL5-H5214 | Human | Human IL-5 Protein, premium grade |
|
||
EP-128 | Human | IL-5[Biotinylated]:IL-5Rα Inhibitor Screening ELISA Kit | |||
IL5-C52H3 | Cynomolgus | Cynomolgus IL-5 Protein, His Tag |
|
||
IL5-M52H3 | Mouse | Mouse IL-5 Protein, His Tag (MALS verified) |
|
||
IL5-R52H4 | Rabbit | Rabbit IL-5 Protein, His Tag |
|
||
IL5-H82Q5 | Human | Biotinylated Human IL-5 Protein, His,Avitag™ |
|
||
IL5-H52H3 | Human | Human IL-5 Protein, His Tag |
|
Human IL-5 Protein, premium grade (Cat. No. IL5-H5214) stimulates proliferation of 293F-STAT5/Luc-IL5RA-CD131-9 cells. The specific activity of Human IL-5 Protein, premium grade is > 3.00ⅹ10^6 IU/mg, which is calibrated against human IL-5 WHO International Standard (NIBSC code: 90/586) (QC tested).
Loaded Human IL-5 Protein, His Tag (Cat. No. IL5-H52H3) on NTA Biosensor, can bind Human IL-5 R alpha, Fc Tag with an affinity constant of 4.63 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
INHIBITION OF IL-5 [BIOTINYLATED]: IL-5 R ALPHA BINDING BY Human IL-5
Serial dilutions of Human IL-5(Catalog # EP128-C03) (1:1 serial dilution, from 10 μg/mL to 0.020 μg/mL (666.67-0.65 nM)) was added into IL-5 R alpha: IL-5-Biotin binding reactions. The assay was performed according to the above-described protocol. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Reslizumab | TRFK-5; CDP-835; SCH-5570; CEP-38072; CTx-55700; SCH-55700 | Approved | Teva Pharmaceutical Industries Ltd | Cinqair, Cinquil, Cinqaero | United States | Asthma | Teva Respiratory Llc | 2016-03-23 | Hypereosinophilic Syndrome; Loiasis; Pulmonary Eosinophilia; Eosinophilic Esophagitis; Asthma; Bronchitis | Details |
Mepolizumab | SB-240563; 240563 | Approved | Glaxosmithkline Plc | Bosatria, Nucala, 美泊利珠单抗 | United States | Asthma | Glaxosmithkline Llc | 2015-11-04 | Granulomatosis with Polyangiitis; Hypereosinophilic Syndrome; Eosinophilic Granulomatosis With Polyangiitis; Nasal Polyps; Eosinophilia; Chronic Urticaria; Nose Diseases; Virus Diseases; Eosinophilic Esophagitis; Sinusitis; Asthma; Bronchitis; Pulmonary Disease, Chronic Obstructive; Fasciitis; Dermatitis, Atopic; Angioedema | Details |
Reslizumab | TRFK-5; CDP-835; SCH-5570; CEP-38072; CTx-55700; SCH-55700 | Approved | Teva Pharmaceutical Industries Ltd | Cinqair, Cinquil, Cinqaero | United States | Asthma | Teva Respiratory Llc | 2016-03-23 | Hypereosinophilic Syndrome; Loiasis; Pulmonary Eosinophilia; Eosinophilic Esophagitis; Asthma; Bronchitis | Details |
Mepolizumab | SB-240563; 240563 | Approved | Glaxosmithkline Plc | Bosatria, Nucala, 美泊利珠单抗 | United States | Asthma | Glaxosmithkline Llc | 2015-11-04 | Granulomatosis with Polyangiitis; Hypereosinophilic Syndrome; Eosinophilic Granulomatosis With Polyangiitis; Nasal Polyps; Eosinophilia; Chronic Urticaria; Nose Diseases; Virus Diseases; Eosinophilic Esophagitis; Sinusitis; Asthma; Bronchitis; Pulmonary Disease, Chronic Obstructive; Fasciitis; Dermatitis, Atopic; Angioedema | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Recombinant anti-IL-5 humanized monoclonal antibody (Shanghai CP Guojian) | 610; SSGJ-610 | Phase 3 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Autoimmune Diseases; Asthma | Details |
SHR-1703 | SHR-1703 | Phase 3 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Eosinophilic Granulomatosis With Polyangiitis; Asthma | Details |
Depemokimab | GSK-294; GSK3511294; GSK294; GSK-3511294 | Phase 3 Clinical | Glaxosmithkline Plc | Hypereosinophilic Syndrome; Eosinophilic Granulomatosis With Polyangiitis; Nasal Polyps; Vasculitis; Asthma; Eosinophilic Granuloma; Sinusitis | Details |
long-acting anti-IL-5 mAb (GSK) | Phase 1 Clinical | Glaxosmithkline Plc | Asthma | Details | |
KBL-693 | KBL-693 | Phase 1 Clinical | Kobiolabs | Asthma | Details |
Mepolizumab biosimilar(Bio Thera Solutions) | BAT2606; BAT-2606 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Nasal Polyps; Autoimmune Diseases; Sinusitis; Asthma | Details |
RC-1416 | Phase 1 Clinical | Nanjing Rongjiekang Biotechnology Co Ltd | Asthma | Details | |
Mepolizumab biosimilar (CTTQ Pharma) | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Granulomatosis with Polyangiitis; Hypereosinophilic Syndrome; Vasculitis; Nasal Polyps; Asthma; Eosinophilic Granuloma; Sinusitis; Lymphohistiocytosis, Hemophagocytic | Details | |
Recombinant anti-IL-5 humanized monoclonal antibody (Shanghai CP Guojian) | 610; SSGJ-610 | Phase 3 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Autoimmune Diseases; Asthma | Details |
SHR-1703 | SHR-1703 | Phase 3 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Eosinophilic Granulomatosis With Polyangiitis; Asthma | Details |
Depemokimab | GSK-294; GSK3511294; GSK294; GSK-3511294 | Phase 3 Clinical | Glaxosmithkline Plc | Hypereosinophilic Syndrome; Eosinophilic Granulomatosis With Polyangiitis; Nasal Polyps; Vasculitis; Asthma; Eosinophilic Granuloma; Sinusitis | Details |
long-acting anti-IL-5 mAb (GSK) | Phase 1 Clinical | Glaxosmithkline Plc | Asthma | Details | |
KBL-693 | KBL-693 | Phase 1 Clinical | Kobiolabs | Asthma | Details |
Mepolizumab biosimilar(Bio Thera Solutions) | BAT2606; BAT-2606 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Nasal Polyps; Autoimmune Diseases; Sinusitis; Asthma | Details |
RC-1416 | Phase 1 Clinical | Nanjing Rongjiekang Biotechnology Co Ltd | Asthma | Details | |
Mepolizumab biosimilar (CTTQ Pharma) | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Granulomatosis with Polyangiitis; Hypereosinophilic Syndrome; Vasculitis; Nasal Polyps; Asthma; Eosinophilic Granuloma; Sinusitis; Lymphohistiocytosis, Hemophagocytic | Details |
This web search service is supported by Google Inc.